Overview / Abstract: |
Although outcomes for patients with multiple myeloma (MM) have improved with targeted agents and combination therapies, most MM patients inevitably relapse. Furthermore, the duration and quality of response to treatment deteriorates following each subsequent line of therapy, and the risk of another relapse rises. The emergence of B-cell maturation antigen (BCMA)-targeting antibody-drug conjugates, bispecific antibodies, CAR T-cell therapy, and novel small-molecule agents has offered innovative treatment options for patients with MM that has relapsed or become refractory (RRMM) to several lines of therapy. This activity has been developed to present and discuss current recommended strategies for individualizing treatment plans for patients with RRMM by incorporating the most up-to-date clinical evidence on sequencing small molecule"based therapies and BCMA-targeted therapies that achieve durable remission while minimizing toxicity. |
Expiration |
Sep 30, 2023 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Online |
Credits / Hours |
1.0 |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Amrita Y. Krishnan, MD Saad Z. Usmani, MD, MBA, FACP |
Activity Specialities / Related Topics |
Hematology, Oncology / Cancer / Radiation Therapy |
Sponsors / Supporters / Grant Providers |
Support for this activity has been provided through educational grants from GSK and Pfizer. |
Keywords / Search Terms |
RedMedEd RedMedEd, B-cell maturation antigen, BCMA, belantamab mafodotin, belmaf, bispecific antibodies, bortezomib, carfilzomib, CAR T-cell therapy, cilta-cel, ciltacabtagene autoleucel, CRS, cytokine release syndrome, daratumumab, dexamethasone, elranatamab, iberdomide, idecabtagene vicleucel, immunotherapy, lenalidomide, pomalidomide, relapsed/refractory multiple myeloma, selinexor, talquetamab, teclistamab, tocilizumab, venetoclax Free CE CME |